Invasive lobular carcinoma: Correlations between morphological features, vimentin expression, oestrogen receptor status and prognosis

Breast

Volumn 6, Issue 2, 1997, Pages 89-96

  Kubiak, R ^a,b   Szadowska, A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Oncology ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; VIMENTIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

EID: 0030990924     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(97)90180-6     Document Type: Article

References (44)

1. Zatoński W, Tyczyński J. Nowotwory złośliwe w Polsce w 1990 roku. Zakład organizacji walki z rakiem i epidemiologii nowotworów. Krajowy Rejestr Nowotworów. Warszawa 1993.
2. DiCostanzo D, Rosen P P, Gareen I, Franklin S, Lesser M. Prognosis in infiltrating lobular carcinoma. Analysis of 'classical' and variant tumours. Am J Surg Pathol 1990; 14(1): 12-23.
3. Van Bogaert L-J, Maldague P. Infiltrating lobular carcinoma of the female breast. Deviations from the usual histopathologic appearance. Cancer 1980; 45: 979-984.
4. Martinez V, Azzopardi J D. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979; 3: 467-488.
5. Bloom H J G, Richardson W W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
6. Domagała W, Woźniak L, Lasota J, Weber K, Osborn M. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 1990: 137(5): 1059-1064.
7. Raymond W A, Leong A S-Y. Vimentin - a new prognostic parameter in breast carcinoma? J Pathol 1989; 158: 107-114.
8. Thompson E W, Paik S, Brunner N et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992; 150(3): 534-544.
9. Guelstein V I, Tchypysheva T A, Ermilova V D, Litvinova L V, Troyanovsky S M, Baanikov G A. Monoclonal antibody mapping of Keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumours, dysplasias and breast cancer. Int J Cancer 1988; 42: 147-153.
10. Raymond W A, Leong A S-Y. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 1989; 157: 299-306.
11. Gould V E, Koukoulis G K, Jansson D S, Nagle R B, Franke W W, Moll R. Co-expression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am J Pathol 1990; 137(5): 1143-1155.
12. Heatley M, Whiteside C, Maxwell P, Toner P. Vimentin expression in benign and malignant breast epithelium. J Clin Pathol 1993; 46: 441-445.
13. Meyer J S, Rao B R, Stevens S C, White W L. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 1977; 40: 2290-2298.
14. Wong S Y, Kernohan N M, Walker F. Breast cancers with extremely high oestrogen receptor protein status. Histopathology 1990; 16: 125-132.
15. Smith D B, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987; 23(7): 979-982.
16. Shousha S, Backhouse C M, Alaghband-Zadeh J, Burn I. Alveolar variant of invasive lobular carcinoma of the breast. A tumour rich in estrogen receptors. Am J Clin Pathol 1986; 85: 1-5.
17. Howell A, Harris M. Infiltrating lobular carcinoma of the breast. BMJ 1985; 291: 1371-1371.
18. Pari F F, Schmidt B P, Dupont W D, Wagner R K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumour stage, axillary node metastasis, and histopathologic grading. Cancer 1984; 54: 2237-2242.
19. Dixon J M, Anderson T J, Page D L, Lee D, Duffy S W. Infiltrating lobular carcinoma of the breast. Histopathology 1982; 6: 149-161.
20. Fechner R E. Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 1975; 6(3): 373-378.
21. Domagata W, Lasota J, Bartkowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990; 136: 219-227.
22. Szadowska A, Lasota J, Kubiak R, Graczyk G. Evaluation of estrogen receptor immunocytochemical assay (ER-ICA) and estrogen receptor enzyme immunoassay (ER-EIA) for the determination of estrogen receptor status in breast carcinoma. A comparative study on frozen sections, cytological smears and tissue homogenates. Pat Pol 1991; 42: 17-23.
23. Eusebi V, Magalhaes F, Azzopardi J G. Pleomorphic lobular carcinoma of the breast: an aggressive tumour showing apocrine differentiation. Hum Pathol 1992; 26: 655-662.
24. Weidner N, Semple J P. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992; 23: 1167-1171.
25. Shousha S, Bull T B, Burn I. Alveolar variant of invasive lobular carcinoma of the breast: an electron microscopic study. Ultrastruct Pathol 1986; 10: 311-319.
26. Simpson J F, Page D L. Prognostic value of histopathology in the breast. Semin Oncol 1992; 19(3): 254-262.
27. Primus F J, Kuhns W J, Goldenberg D M. Immunological heterogeneity of carcinoembrionic antigen: immunohistochemical detection of carcinoembrionic antigen determinants in colonic tumours with monoclonal antibodies. Cancer Res 1983; 43: 693-701.
28. Batsakis J G, Sneige N, El-Naggar A K. Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer. Cancer 1993; 71: 2151-2153.
29. Clark G M, Wenger C R, Beardslee S et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993; 71: 2157-2162.
30. Elledge R M, McGuire W L, Osborne C K. Prognostic factors in breast cancer. Semin Oncol 1992; 19(3): 244-253.
31. Kreipe H, Heiderbrecht H J, Hansen S et al. A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 1993; 142(1): 3-10.
32. Siitonen S M, Isola J J, Rantala I S, Helin H J. Intratumour variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am J Clin Pathol 1993; 99: 226-231.
33. Mansour E G, Hastert M, Park C H, Koehler K A, Petrelli M. Tissue and plasma carcinoembrionic antigen in early breast cancer. A prognostic factor. Cancer 1983; 51: 1243-1248.
34. Parham D M, Hagen N, Brown R A. Simplified method of grading primary carcinomas of the breast. J Clin Pathol 1992; 45: 517-520.
35. Stenkvist B, Bengtsson E, Dahlqvist B et al. Predicting breast cancer recurrence. Cancer 1982; 50: 2884-2893.
36. Sunderland M C, McGuire W L. Prognostic indicators in invasive breast cancer. Surg Clin North Am 1990; 70(5): 989-1004.
37. Domagałe W, Harezga B, Szadowska A, Markiewicz M, Weber K, Osborn M. Nuclear p53 protein accumulates preferentially in medullary and high grade ductal but rarely in lobular breast carcinomas. Am J Pathol 1993; 142: 669-674.
38. Martinez-Hernandez A, Francis D J, Silverberg S G. Elastosis and other stromal reactions in benign and malignant breast tissue. An ultrastructural study. Cancer 1977; 40: 700-706.
39. Azzopardi J G, Laurini R N. Elastosis in breast cancer. Cancer 1974; 33: 174-183.
40. Fisher E R, Anderson S, Redmond C, Fisher B and NSABP collaborating investigators. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. Ten year pathologic and clinical prognostic discriminants. Cancer 1993; 71: 2507-2514.
41. Fisher E R, Carol K R, Liu H, Rockelle H, Fisher B and collaborating NSABP investigators. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 1980; 45: 349-353.
42. Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer 1988; 57: 353-367.
43. Domagała W, Lasota J, Dukowicz A et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 1990; 137: 001-006.
44. Thorpe S M, Christensen Ib J, Rasmussen B B, Rose C. Short recurrence-free survival association with high oestrogen receptor levels in natural history of postmenopausal, primary breast cancer. Eur J Cancer 1993; 29A: 971-977.